Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dermatophagoides pteronyssinus allergoid (glutaraldehyde-modified)
- Development stage
- Phase 3
- Lead developer
- Roxall Medizin
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Dermatophagoides pteronyssinus allergoid (glutaraldehyde-modified) is a modified allergen extract used in allergen immunotherapy (AIT) for the treatment of house dust mite-induced allergic rhinitis and rhinoconjunctivitis. Developed by ROXALL Medizin GmbH, this allergoid is produced by treating the native allergens of the European house dust mite with glutaraldehyde. This chemical modification induces polymerization, which significantly reduces the allergen's IgE-binding capacity (allergenicity) while preserving its ability to stimulate T-cells (immunogenicity). By reducing IgE-mediated side effects, the allergoid allows for the administration of higher allergen doses, facilitating a more rapid and effective induction of immunological tolerance. The treatment works by shifting the immune response from a Th2-dominated allergic profile to a Th1 and regulatory T-cell (Treg) profile, characterized by the production of blocking IgG4 antibodies and anti-inflammatory cytokines like IL-10. It is typically administered as a subcutaneous injection (SCIT) and is often adsorbed onto aluminum hydroxide to enhance its immunogenic effect.
- Brand names
- CLUSTOIDMurex
- Other names
- Dermatophagoides pteronyssinus allergoidGlutaraldehyde-modified house dust mite allergoid
Beyond the preview
Go deeper on dermatophagoides pteronyssinus allergoid (glutaraldehyde-modified).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dermatophagoides pteronyssinus allergoid (glutaraldehyde-modified).